To explore the clinical efficacy of Jianpi Lishi Jiedu Decoction（健脾利湿解毒汤）combined with pidotimod in the treatment of low-grade squamous intraepithelial lesions（LSIL）of the cervix combined with high-risk human papillomavirus（HPV）infection.

A totalof130 cases of LSIL complicated with high-risk HPV infection admitted to the hospital from January 2022 to September 2023 were included and divided into two groups using the computer random number table method，with 65 cases in each group.The control group was treated with pidotimod，while the observation group was treated with Jianpi Lishi Jiedu Decoction on the basis of the control group.The treatment lasted for 3 months.The clinical efficacy of two groups，the traditional Chinese medicine syndrome score and serum inflammatory factor levels［high-sensitivity C-reactive protein（hs-CRP），interleukin-12（IL-12）and tumor necrosis factorα（TNF）-α）］and changes in viral load were compared.

①The total effective rate of the observation group was 93.85%，which was higher than that（81.54%）of the control group（χ²＝4.561，P＝0.033）.②The difference in traditional Chinese medicine syndrome scores for vaginal discharge，itching，fatigue，edema and loose stools in the observation group was lower than that in the control group［（1.13±0.13）points vs.（2.05±0.16）points，（1.09±0.11）points vs.（1.65±0.15）points，（1.01±0.19）points vs.（1.66±0.22）points，（0.68±0.17）points vs.（1.13±0.19）points，（0.89±0.18）points vs.（1.38±0.14）points］（t＝35.979～17.324，all P<0.01）.③The serum levels of TNF-α and hs-CRP of the observation group were all lower than those of the control group［（1.13±0.36）pg/mL vs.（1.72±0.41）pg/mL，（2.19±0.45）mg/L vs.（4.24±0.87）mg/L］（t＝8.718-16.874，all P<0.01），and the serum IL-12 levels were higher than the control group［（16.52±5.03）pg/mL vs.（14.25±5.16）pg/mL］（t＝-2.540，P＝0.006）.④The recurrence rate［4.61%（3/65）］in the observation group was significantly lower than that［16.92%（11/65）］in the control group（χ²＝5.123，P＝0.024）.The HPV viral load in the observation group was lower than that in the control group［（1.85±0.59）Igcopies/mL vs.（2.73±0.65）Igcopies/mL］（t＝-8.082，P<0.01），and the seroconversion rate was higher than that in the control group（69.23% vs.43.08%）（χ² ＝9.029，P＝0.003）.

The combination of Jianpi Lishi Jiedu Decoction and pidotimod in the treatment of LSIL complicated with high-risk HPV infection has a definite therapeutic effect.It can restore the patient's immune inflammatory balance and reduce the HPV viral load.